Annexon (NASDAQ:ANNX) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Annexon (NASDAQ:ANNX) in a research report sent to investors on Friday morning,Benzinga reports.

ANNX has been the subject of a number of other research reports. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research report on Friday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.80.

Annexon Price Performance

Shares of ANNX traded down $0.21 during mid-day trading on Friday, reaching $6.12. The stock had a trading volume of 1,917,213 shares, compared to its average volume of 1,819,268. Annexon has a 52-week low of $2.27 and a 52-week high of $8.40. The firm has a market cap of $646.58 million, a price-to-earnings ratio of -4.98 and a beta of 1.23. The business’s fifty day moving average is $6.91 and its 200 day moving average is $5.92.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 5,500 shares of Annexon stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $5.64, for a total value of $31,020.00. Following the completion of the sale, the executive vice president now owns 10,000 shares in the company, valued at approximately $56,400. This trade represents a 35.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 20,908 shares of company stock worth $135,768. 12.67% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Annexon

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after acquiring an additional 331,269 shares in the last quarter. Barclays PLC increased its stake in Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 120,789 shares during the period. Wellington Management Group LLP lifted its position in shares of Annexon by 36.2% during the third quarter. Wellington Management Group LLP now owns 263,360 shares of the company’s stock worth $1,559,000 after purchasing an additional 69,941 shares in the last quarter. State Street Corp boosted its stake in shares of Annexon by 116.6% in the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after purchasing an additional 2,068,294 shares during the period. Finally, Quarry LP acquired a new position in shares of Annexon in the third quarter valued at approximately $118,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.